Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190100 | 0.90 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL12190091 | 0.90 | NPC1 (0.71) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3786373 | 0.86 | SMO (0.64) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL5832371 | 0.86 | MAPT (0.61) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3789815 | 0.86 | PPARG (0.74) | MEN1KMT2AMAPTPKMHDAC8 | |
| SCHEMBL12190102 | 0.86 | KDM4E (0.72) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL4254150 | 0.86 | MEN1 (0.80) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL3644788 | 0.85 | NPC1 (0.73) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL13349339 | 0.85 | MAPT (0.59) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL14724651 | 0.85 | TAS1R3 (0.60) | MEN1KMT2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | HRH4, VIPR1, TAAR1 | MEN1 1534/4885KMT2A 1844/4885NPC1 3272/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MEN1 1233/4885KMT2A 632/4885NPC1 869/4885 |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | TPH1, GPR119, TAAR1 | MEN1 817/4885KMT2A 1425/4885NPC1 935/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | MEN1 303/4885KMT2A 41/4885NPC1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.